Erica D. Warlick

4.5k citations

109 papers · 2.4k indexed · 1 hit paper · h-index 25

Hematology top 0.5%
- Acute Myeloid Leukemia Research 65
- Hematopoietic Stem Cell Transplantation 60
- Chronic Myeloid Leukemia Treatments 8
Immunology top 5%
- Immune Cell Function and Interaction 15
Oncology top 5%
- CAR-T cell therapy research 7
Transplantation top 5%
Genetics top 5%
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 34
Molecular Biology
- Histone Deacetylase Inhibitors Research 11
Epidemiology
- Cytomegalovirus and herpesvirus research 9

Co-authors: Daniel J. Weisdorf Jeffrey S. Miller Claudio G. Brunstein Todd E. DeFor Michael R. Verneris Daniel A. Vallera Bruce R. Blazar Adina Cioc
Cited by: Hematology Immunology Oncology
Journals: Journal of Clinical Oncology (3 papers)Blood (25 papers)Cancer (1 paper)
Partner nations: United States Spain France

In The Last Decade

Erica D. Warlick

105 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Erica D. Warlick

Since Specialization

Citations

This map shows the geographic impact of Erica D. Warlick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erica D. Warlick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erica D. Warlick more than expected).

Fields of papers citing papers by Erica D. Warlick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erica D. Warlick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erica D. Warlick. The network helps show where Erica D. Warlick may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Erica D. Warlick, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Erica D. Warlick Line = papers co-authored together Erica D. Warlick links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia Blood Advances ·Farhad Ravandi,Sravanti Rangaraju,Hagop M. Kantarjian,Guillermo Garcia‐Manero,Musa Yılmaz,Kristen Baker,Terence Hall,John D. Grabenstein,Pourab Roy,Beth Ann Zamboni,William C. Zamboni,Erica D. Warlick,Michael J. Kelly,David A. Roth,Gabriel Ghiaur	2025	1
2	A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML Leukemia Research ·Jonathan Webster,Tara M. Robinson,Amanda L. Blackford,Erica D. Warlick,Anna Ferguson,Ivan Borrello,Marianna Zahurak,Richard J. Jones,B. Douglas Smith	2021	4
3	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings Blood Advances ·Margaret L. MacMillan,Keli L. Hippen,David H. McKenna,Diane Kadidlo,Darin Sumstad,Todd E. DeFor,Claudio G. Brunstein,Shernan G. Holtan,Jeffrey S. Miller,Erica D. Warlick,Daniel J. Weisdorf,John E. Wagner,Bruce R. Blazar	2021	54
4	Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant Bone Marrow Transplantation ·Okoev Gg,Daniel J. Weisdorf,John E. Wagner,Bruce R. Blazar,Margaret L. MacMillan,Todd E. DeFor,Aleksandr Lazaryan,Najla El Jurdi,Shernan G. Holtan,Claudio G. Brunstein,Brian C. Betts,Takuto Takahashi,Veronika Bachanová,Erica D. Warlick,Armin Rashidi,Mukta Arora	2021	4
5	GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts Blood ·Erica D. Warlick,Daniel J. Weisdorf,Daniel A. Vallera,Rose Wangen,Dixie Lewis,JoAnn Knox,Martin Schroeder,Martin Felices,Jeffrey S. Miller	2020	29
6	Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function JCI Insight ·Dhifaf Sarhan,Jinhua Wang,Upasana Sunil Arvindam,Caroline Hallstrom,Michael R. Verneris,Bartosz Grzywacz,Erica D. Warlick,Bruce R. Blazar,Jeffrey S. Miller	2020	40
7	Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis Biology of Blood and Marrow Transplantation ·Armin Rashidi,Mohamad Aghaie Meybodi,Wenhao Cao,Haitao Chu,Erica D. Warlick,Steven M. Devine,Marcelo C. Pasquini,Daniel J. Weisdorf,Mehdi Hamadani	2020	9
8	Prognostic factors for clinical outcomes of patients with central nervous system leukemia Hematology/Oncology and Stem Cell Therapy ·Jinai Bharucha,Qing Cao,Zohar Sachs,Angela R. Smith,Sarah Williams,Khalid Amin,Veronika Bachanová,Erica D. Warlick,Claudio G. Brunstein,Daniel J. Weisdorf,Nelli Bejanyan	2020	3
9	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up Biology of Blood and Marrow Transplantation ·Erica D. Warlick,Todd E. DeFor,Nelli Bejanyan,Shernan G. Holtan,Margaret L. MacMillan,Bruce R. Blazar,Kathryn E. Dusenbery,Mukta Arora,Veronika Bachanová,Sarah Cooley,Aleksandr Lazaryan,Philip B. McGlave,Jeffrey S. Miller,Armin Rashidi,Arne Slungaard,Gregory M. Vercellotti,Celalettin Üstün,Claudio Brunsein,Daniel J. Weisdorf	2018	8
10	Absence of early HHV‐6 reactivation after cord blood allograft predicts powerful graft‐versus‐tumor effect American Journal of Hematology ·Armin Rashidi,Maryam Ebadi,Bassil Said,Qing Cao,Ryan Shanley,Julie Curtsinger,Nelli Bejanyan,Erica D. Warlick,Jaime S. Green,Claudio G. Brunstein,Jeffrey S. Miller,Daniel J. Weisdorf	2018	2
11	Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics Haematologica ·Fatma Keklik Karadağ,Ezzideen Barjes Alrawi,Qing Cao,Nelli Bejanyan,Armin Rashidi,Aleksandr Lazaryan,Patrick Arndt,Erhan H. Dincer,Veronika Bachanová,Erica D. Warlick,Margaret L. MacMillan,Mukta Arora,Jeffrey S. Miller,Claudio G. Brunstein,Daniel J. Weisdorf,Celalettin Üstün	2018	20
12	Multiple transmissions of chromosomally integrated human herpesvirus‐6 in one family Transplant Infectious Disease ·Armin Rashidi,Karam M. Obeid,Joshua A. Hill,Erica D. Warlick,Daniel J. Weisdorf	2017	0
13	History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease‐negative first complete remission American Journal of Hematology ·Armin Rashidi,Michael A. Linden,Todd E. DeFor,Erica D. Warlick,Nelli Bejanyan,Sophia Yohe,Daniel J. Weisdorf,Celalettin Üstün	2017	15
14	MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes Bone Marrow Transplantation ·Hoda Pourhassan,Todd E. DeFor,Bryan Trottier,Michelle Dolan,Claudio G. Brunstein,Nelli Bejanyan,(unknown),Erica D. Warlick	2016	3
15	Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies Leukemia Research ·Kelly J. Norsworthy,Eunpi Cho,Jyoti Arora,Jeanne Kowalski,Hua-Ling Tsai,Erica D. Warlick,Margaret M. Showel,Keith W. Pratz,Lesley Sutherland,Steven D. Gore,Anna Ferguson,Sarah Sakoian,Jackie Greer,Igor Espinoza‐Delgado,Richard J. Jones,William Matsui,B. Douglas Smith	2016	11
16	Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes Cancer Epidemiology ·Jenny N. Poynter,Michaela Richardson,Cindy K. Blair,Michelle A. Roesler,Betsy Hirsch,Phuong Nguyen,Adina Cioc,Erica D. Warlick,James R. Cerhan,Julie A. Ross	2015	64
17	Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning for Older Patients with Acute Myelogenous Leukemia Biology of Blood and Marrow Transplantation ·Régis Peffault de Latour,Claudio G. Brunstein,Raphaël Porcher,Patrice Chevallier,Marie Robin,Erica D. Warlick,Aliénor Xhaard,Celalettin Üstün,Jérôme Larghero,Nathalie Dhédin,Mohamad Mohty,Gèrard Socié,Daniel J. Weisdorf	2013	61
18	Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions Current Opinion in Oncology ·Erica D. Warlick	2010	1
19	Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes Leukemia Research ·Erica D. Warlick,Paul V. O’Donnell,Michael J. Borowitz,Nichon L. Grupka,Lauren Decloe,Elizabeth Garrett‐Mayer,Ivan Borrello,Robert A. Brodsky,Ephraim J. Fuchs,Carol Ann Huff,Leo Luznik,William Matsui,Richard F. Ambinder,Richard J. Jones,B. Douglas Smith	2008	13
20	Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches Current Cancer Drug Targets ·Erica D. Warlick,Benjamin D. Smith	2007	24

About Erica D. Warlick

Erica D. Warlick is a scholar working on Hematology, Transplantation and Public Health, Environmental and Occupational Health, having authored 109 papers that have together received 2.4k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (65 papers), Hematopoietic Stem Cell Transplantation (60 papers), Acute Lymphoblastic Leukemia research (34 papers), Immune Cell Function and Interaction (15 papers), Histone Deacetylase Inhibitors Research (11 papers), Cytomegalovirus and herpesvirus research (9 papers), Chronic Myeloid Leukemia Treatments (8 papers) and CAR-T cell therapy research (7 papers). The work is most often cited by research in Hematology (1.6k citations), Immunology (812 citations) and Oncology (858 citations). Erica D. Warlick has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Daniel J. Weisdorf, Jeffrey S. Miller, Claudio G. Brunstein, Todd E. DeFor, Michael R. Verneris, Daniel A. Vallera, Bruce R. Blazar, Adina Cioc, Julie A. Ross and Michelle Dolan. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact